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ABSTRACT
Purpose
Concerns about radiotherapy-related neurocognitive 
sequelae in young children have led to deferral or 
avoidance of radiation in contemporary treatment 
for this fragile group of patients. We compared sur-
vival and neurocognitive outcome in two groups of 
infants with medulloblastoma who received adjuvant 
conventional craniospinal irradiation (csi) or reduced 
or no radiotherapy during an era of change in the 
philosophy of infant medulloblastoma treatment.
Patients and Methods
From 1985 to 2007, 29 patients 3 years of age or 
younger were diagnosed and treated with curative 
intent in our institution. Children treated before 1994 
received adjuvant radiation with chemotherapy; sub-
sequently, radiation was prescribed essentially for 
disease progression or relapse.
Results
Median age at diagnosis was 24 months (range: 
1–36 months); 15 patients (52%) presented with 
metastatic disease at diagnosis. As part of initial 
treatment, 8 children received adjuvant radiotherapy 
with chemotherapy, and 21 children received post-
operative chemotherapy only. Five children treated 
with chemotherapy alone are in prolonged remis-
sion. The 5-year event-free and overall survivals 
were 35.9% ± 9.8% and 50.2% ± 9.6% respectively. 
Extent of resection, metastatic status, and desmo-
plastic histology were not found to be significant 
prognostic factors.
On serial neurocognitive evaluations, patients 
treated with chemotherapy with or without reduced 
radiotherapy demonstrated improvement of intel-
lectual function over time. Patients treated with 
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conventional csi exhibited significantly lower intel-
ligence quotient scores and academic performance, 
with the exception of receptive vocabulary.
Conclusions
Avoidance of conventional csi in treatment of very 
young children with medulloblastoma appears to be 
associated with a preserved neurocognitive profile. 
Neurocognitive evaluation should be integrated into 
the primary objectives of future infant protocols.
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1.  INTRODUCTION
Medulloblastoma is the most common malignant 
brain tumour in children. Of all medulloblastomas, 
30% occur in children under 3 years of age 1, and 
this population is a very challenging group because 
of their recognized poorer outcome and, most im-
portantly, because of their increased susceptibility 
to treatment-related toxicities. Infants with brain 
tumours are particularly vulnerable to significant 
intellectual impairment after cranial irradiation 2–5. 
Although craniospinal irradiation (csi) improves 
survival, it is usually avoided in young children 
because of significant neurotoxicity and very adverse 
neurocognitive outcomes. To delay or eliminate the 
need for radiation at this early stage of brain matu-
ration, a series of contemporary therapeutic studies 
relying on primary postoperative chemotherapy have 
been developed for infants and young children 6–10. 
Preserved intellectual outcome has been documented 
for survivors treated without radiation, but compre-
hensive long-term longitudinal data remain limited 
to date 11,12. Here, we report a single-institution ex-
perience in managing infants with medulloblastoma 
over a 20-year period and provide comprehensive 22
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serial neurocognitive data on long-term survivors.
2.  PATIENTS AND METHODS
At the Hospital for Sick Children in Toronto, 34 con-
secutive patients diagnosed with medulloblastoma 
before the age of 3 years were treated between April 
1985 and April 2007. This retrospective review of 
those 34 cases was approved by the research eth-
ics board of the institution. Clinical, therapeutic, 
and survival data were collected from patient files. 
Patient outcomes included serial neurocognitive 
measures and endocrine status at completion of 
the study.
Metastatic status according to the Chang staging 
system 13 and extent of resection were based on the 
cerebrospinal fluid (csf) analysis (when available), 
the surgical report, and postsurgical imaging. Extent 
of resection was defined as follows:
●    Gross total resection (gtr)—no radiologic evidence 
of residual tumour
●    Radical subtotal resection (rstr)—a resection of less 
than 100%, but of 95% or more
●    Subtotal resection (str)—a resection of less than 
95%, but of more than 50%
●    Partial resection (pr)—a resection of less than 49%, 
but of 10% or more
●    Biopsy—a resection of less than 10%
All tumour samples were reviewed by one neuro-
pathologist (CH) for the purposes of the study.
Clinical management evolved over the study pe-
riod. Before 1994, all patients treated with curative 
intent received adjuvant chemotherapy and radio-
therapy. After 1994, all infants with medulloblastoma 
were treated according to “baby brain” protocols and 
strategies 7,8, those successively being Baby pog (Pe-
diatric Oncology Group) 1 and 2, and bbsfop (Societe 
francaise d’oncologie pediatrique).
More recently, in an attempt to improve outcome, 
high-dose chemotherapy (hdc) protocols were intro-
duced into the management of these children.
2.1  Neuropsychological Assessment
Neurocognitive assessments were conducted for 
all surviving patients. These assessments included 
evaluation of intelligence, receptive vocabulary, 
visual–motor function, memory, and academic 
achievement. Specifically, the test battery included 
either the Wechsler Intelligence Scale for Children 
(3rd edition) or the Wechsler Preschool and Pri-
mary Scales of Intelligence–Revised depending 
on the age of the child and the Peabody Picture 
Vocabulary Test, the Beery Visual–Motor Integra-
tion Test, the Children’s Memory Scale, and the 
Wide Range Achievement Test (either revised or 
3rd edition).
2.2  Statistical Analysis
Progression-free survival (pfs) was determined from 
the date of diagnosis to the date of disease progres-
sion, with censoring on the date of the most recent 
clinical assessment. Overall survival (os) was as-
sessed from the date of the diagnosis to the date of 
last follow-up or the date of death. Kaplan–Meier 
analysis was used to estimate os and pfs, and the 
log-rank test was used to determine statistical sig-
nificance. For neurocognitive assessment, individual 
test scores were converted to standard scores (based 
on age-related means and standard deviations from 
test standardization norms) with a mean of 100 and 
a standard deviation of 15. Analysis of variance was 
used to examine group differences in neurocognitive 
functioning for the survivors. All statistical analyses 
were performed using the SPSS software package 
(version 15.0: SPSS, Chicago, IL, U.S.A.).
3.  RESULTS
3.1  Patient Characteristics at Diagnosis
From April 1985 to April 2007, 34 consecutive pa-
tients (19 boys, 15 girls) with a histologically con-
firmed diagnosis of medulloblastoma were diagnosed 
and treated at our institution. All were 36 months 
of age or younger. Median age at diagnosis was 24 
months (range: 1–36 months), and 7 patients were less 
than 12 months old. Median duration of presenting 
symptoms before diagnosis was 0.8 month (range: 
1 week to 6 months).
All patients underwent a surgical procedure, and 
5 patients subsequently received postoperative pallia-
tion for extensive disease and poor surgical recovery. 
The patient characteristics, treatment descriptions, 
and outcomes data that follow are therefore given for 
the 29 patients who received postoperative therapy 
with curative intent. Of these 29 patients, 17 under-
went gtr or rstr (≥95% resection), 10 underwent str, 
and 2 underwent pr.
In 6 patients (21%), staging investigations (cran-
iospinal axis imaging and  csf cytology analysis) 
were insufficient to provide an accurate metastatic 
status at diagnosis. Metastasis at diagnosis was 
found in 15 patients (52%: 4 M1, 4 M2, 6 M3, 1 
M2/M3). Histopathologic subtype was desmoplastic 
in 7 patients (24.1%), anaplastic in 1 patient (3.4%, 
and classic medulloblastoma in the remaining 21 
patients (72.5%).
3.2  Chemotherapy
Chemotherapy with curative intent was prescribed in 
all 29 patients. Table i details the chemotherapy regi-
mens used. Adjuvant chemotherapy alone was used in 
21 patients, with the intent to delay or avoid radiation. 
This chemotherapy-alone strategy was successfully 23
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of 81 months, 6 of the 8 irradiated patients (75%) 
remain alive.
In 4 patients, salvage radiotherapy was adminis-
tered at the time of recurrence or progression. Of these 
4 patients, 2 received conventional csi, 1 received 
stereotactic radiation (5400 cGy) to the tumour bed 
after hdc and scr, and 1 received a reduced dose of 
csi (1800 cGy), with a posterior fossa boost, for local 
relapse 1 year after high-dose chemotherapy. Only 1 
of these 4 patients patient is a long-term survivor at 
108 months from diagnosis.
3.4  Survival and PFS
Deaths from their disease occurred in 15 patients, 
from a secondary malignancy (T-cell lymphoma) 
in 1 patient, and from treatment-related toxicity in 
1 patient. At a median follow-up of 90 months (range: 
23–194 months), 12 patients remain alive. Progres-
sion or relapse was focal in 7 patients (41%), distant 
in 3 patients (18%), and combined focal and distant 
in 7 patients (41%).
The 5-year pfs and os were 35.9% ± 9.8% and 
50.2% ± 9.6% respectively. None of the following 
factors were found to be significant for os and event-
free survival: age younger than 12 months, extent 
of resection, and desmoplastic histology. Although 
nonsignificant, a trend for a better survival was ob-
served in patients presenting with metastatic disease 
at diagnosis (5-year os of 64.2% ± 13.2%, Table ii). 
The use of adjuvant conventional csi was the only 
factor associated with a significantly better 5-year pfs 
(p =0.013) and an os of 72.9% ± 16.5% (p = 0.032).
Table iii summarizes the characteristics of the 
surviving patients.
3.5  Neurocognitive Evaluation
For the 12 surviving patients, neurocognitive outcome 
was compared between the 6 patients treated with 
conventional csi (group A) and the 6 patients treated 
with chemotherapy alone or with chemotherapy as-
sociated with reduced-dose or limited-volume radia-
tion (group B). Group A was considered a historical 
control group.
Age at diagnosis was significantly different 
between the two groups (2.33 years for group A vs. 
1.55 years for group B, p < 0.05). Differences in in-
telligence, receptive vocabulary, visual–motor skills, 
academics, and memory were evaluated at a single 
time (mean of 4.7 years after diagnosis) for all patients. 
Assessment data for each patient were chosen so that 
age at testing (6.87 years in group A vs. 6.44 years 
in group B) and time since diagnosis (4.56 years in 
group A vs. 4.91 years in group B) did not significantly 
differ between the two groups (p > 0.10).
In 10 patients, at least two neuropsychological 
assessments had been administered during follow-up, 
and we used repeated-measures analyses of variance 
table ii  Overall survival according to prognostic factors
Prognostic factor Patients 
(n)
5-Year Os 
(%)
p 
Value
Age < 12 months at diagnosis 7 28.6±17.1 0.54
Resection > 95% 17 58.2±12.1 0.50
Metastatic disease 15 64.2±13.2 0.055
Desmoplastic histology 7 48.5±11 0.69
Use of adjuvant csi 8 72.9±16.5 0.032
os = overall survival; csi = craniospinal irradiation.
table i  Description of postoperative chemotherapy
Regimen Patients (n)
Conventional chemotherapy 29
Baby pog 1, 2 9
ice 7
8-in-1 3
bbsfop 3
moppa 3
hdc+scr conditioning regimens 8
ccg 99703 3
Busulfan thiotepab 2
Headstart ii 2
Etoposide, carboplatin, thiotepab 1
a    One patient received bbsfop after 1 cycle of mopp and 1 prior to 
high-dose busulfan thiotepa.
b    Post conventional chemotherapy.
Baby pog 1,2 = cyclophosphamide, vincristine, cisplatin; ice = 
ifosfamide, carboplatin, etoposide; 8-in-1 = methylprednisolone, 
vincristine; bbsfop = carboplatin, procarbazine, etoposide, cis-
platin, vincristine, cyclophosphamide; mopp = mechlorethamine, 
vincristine, procarbazine, prednisone;  hdc+scr = high-dose 
chemotherapy and stem cell rescue; ccg 99703 = conditioning 
regimen tandem (carboplatin, thiotepa) for 3 cycles; Headstart 
ii = conditioning regimen with carboplatin, thiotepa, etoposide 
(vp-16) for 1 cycle.
completed in 5 of the 21 patients (24%), who remain 
in continuous complete remission 133, 98, 65, 51, 
and 23 months after diagnosis. Myeloablative hdc 
followed by stem cell rescue (scr) was given to 8 
patients: 6 received this therapy as part of consoli-
dation of initial induction therapy, and 2 received it 
at the time of relapse or for residual disease. Among 
these 8 patients, 1 died of toxicity, and 4 remain alive 
at 81, 51, 36, and 23 months post diagnosis. Median 
time to progression or relapse for the patients treated 
with adjuvant chemotherapy alone was 6.7 months 
(range: 0.4–47.7 months).
3.3  Radiation Therapy
Radiation in an adjuvant setting was administered 
in 8 patients, 7 of whom received csi and a focal 
boost. In 1 patient who had an incomplete resec-
tion at diagnosis, intensity-modulated radiotherapy 
(5400 cGy) was administered to the original tumour 
volume after hdc and scr. At a median follow-up 24
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to examine longitudinal outcomes from the first to the 
second assessment. For this serial analysis, patients in 
group A were older (6.20 years at first assessment and 
9.65 years at second assessment) than those in group B 
(3.59 years at first assessment and 7.13 years at second 
assessment). Further, median time from diagnosis to 
first and second assessment was 3.93 years and 7.38 
years respectively for group A, which is longer than 
the comparable medians of 2.14 years and 5.68 years 
for group B. However, given the small sample size, 
group means for age at testing and for times since 
diagnosis were not significantly different.
For all measures, Figure 1 sets out the means and 
standard deviations at 4.7 years of follow-up. Com-
pared with patients treated with chemotherapy with 
or without reduced radiation, patients treated with 
conventional csi demonstrated significantly lower 
standard scores for full-scale intelligence quotient 
(fiq), visual iq (viq), performance iq (piq), receptive 
vocabulary, visual–motor skills, reading, spelling, 
mathematics achievement, and visual memory. The 
difference for verbal memory did not reach statisti-
cal significance. In general, patients treated with 
conventional csi (group A) demonstrated significant 
deficits in neurocognitive function; those treated 
with chemotherapy with or without reduced radia-
tion (group B) exhibited cognitive function within 
the normal range.
A 2×2 (group × assessment) analysis of variance 
with repeated measures on the last variables was 
used to examine changes and stability in fiq, viq, 
piq, receptive vocabulary, and visual–motor skills 
over time. Compared with the patients in group B, 
the patients in group A obtained standard scores that 
were significantly lower for fiq, viq, piq, and visual–
motor functioning across both assessments (p < 0.02, 
Figure 2). An interaction between group and time 
of assessment was significant for fiq, with scores 
increasing from the first to the second assessment for 
group B, but remaining stable for group A. A notable 
exception was receptive vocabulary, which was not 
different between the groups (p > 0.10). Scores fell 
within the low-average range for group A, which was 
their highest level of performance.
3.6  Endocrine Evaluation
Endocrine status assessment at the last clinical visit 
was available for 9 of the 12 survivors (in 3 patients, 
it was still too early after completion of therapy for 
testing). At a mean follow-up of 108 months post 
diagnosis (range: 65–194 months), 6 patients had 
evidence of partial or complete hypopituitarism. Short 
stature at or below the 10th percentile was found in 
5 patients. Of those 5 patients, 2 were on growth hor-
mone (gh) replacement. In 1 case, parents declined 
gh therapy out of concern that gh might stimulate 
tumour progression. Precocious puberty developed in 
1 patient and was treated with luteinizing hormone–
releasing hormone agonist. The 4 patients who did 
not receive csi are endocrinologically intact. Of those 
4 patients, 3 had received chemotherapy alone, and 
1 had received high-dose chemotherapy with focal 
radiation to the tumour bed.
4.  DISCUSSION
The increased neurotoxic susceptibility of infants with 
embryonal tumours of the central nervous system 
has led to the development, since the late 1980s, of 
innovative strategies to delay or avoid the use of radia-
tion. Here, we reviewed survival and neurocognitive 
outcomes in infants treated for medulloblastoma at 
a single institution using these different strategies.
table iii  Characteristics of the survivors
Pt
id
Sex Age at
diagnosis
(years)
Pathology Surgery Shunt
around time
of surgery
Metastatic
status
Treatment rt type
and dose
(cGy)
Age
at rt
(years)
Follow-up
(months)
1 M 1.7 Classic str + M3 ct+rt csi 3500, boost pf 5000 1.9 194
2 M 2.5 Classic gtr + M3 ct+rt csi 2880, boost pf 5040 2.6 173
3 F 0.8 Classic gtr + M0 ct alone — — 133
4 M 1.9 Classic str – M3 ct+rt csi 3500 2.6 126
5 F 0.8 Desmoplastic rstr – M0 ct alone — — 98
6 M 2.2 Classic str + M2 ct+rta csi 4140 2.8 108
7 M 3.0 Desmoplastic gtr + M3 ct+rta csi 3600 3.1 81
8 F 1.4 Classic gtr + M1 hdc+scr+rt imrt to pf 5400 2.0 81
9 M 2.6 Classic gtr + M0 ct alone — — 65
10 M 2.0 Anaplastic gtr – M1 hdc+scr — — 23
11 M 2.0 Desmoplastic gtr – M1 hdc+scr — — 51
12 F 2.0 Classic pr – M2, M3 hdc+scr+rt csi 2160, boost pf 5040 3.2 36
a  Radiotherapy at time of relapse.
Pt = patient; rt = radiotherapy; M = male; str = subtotal resection; ct = chemotherapy; csi = craniospinal irradiation; pf = posterior fossa; 
gtr = gross total resection; F = female; rstr = radical subtotal resection; hdc+scr = high-dose chemotherapy and stem cell rescue; imrt = 
intensity-modulated radiation therapy; pr = partial resection.25
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figure 1  Late effects in survivor patients: neurocognitive outcome at 5 years after diagnosis using the Wechsler Intelligence Scale for Chil-
dren [full scale intelligence quotient (iq), verbal iq, performance iq], the Receptive Vocabulary test, the Beery Visual–Motor Integration Test, 
the Wide Range Achievement Test (reading, spelling, mathematics), and the Children Memory Scale (memory verbal and memory visual). 
* Significantly different at p < 0.05. ** Significantly different at p < 0.01.
figure 2  Longitudinal evaluation at two time points after diagnosis, using the Wechsler Intelligence Scale for Children [verbal intelligence 
quotient (iq), performance iq (piq), full scale iq (fiq)—left panel] and the Receptive Vocabulary test and the Beery Visual–Motor Integration 
Test (right panel) in surviving patients. Group A (Time 1: 3.98 years; Time 2: 7.38 years) received conventional craniospinal radiation. 
Group B (Time 1: 2.14 years; Time 2: 5.68 years) received chemotherapy with or without reduced radiotherapy.26
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The study may have some inherent limitations 
because of its retrospective nature and the prolonged 
time period, encompassing several eras of therapeutic 
strategies. For example, because the clinical data were 
accrued over a long time for children at various ages, 
different versions of the neurocognitive tests were 
used for different individuals. Further, the sample 
size for the neurocognitive comparisons is relatively 
small (although the patient numbers reflect the clini-
cal reality of medulloblastoma). We acknowledge 
that, had a larger sample size been available, then 
the neurocognitive effects may have been more 
pronounced. Despite the foregoing limitations, our 
study is unique in that it provides comprehensive 
longitudinal neurocognitive follow-up not evident in 
the current literature.
The 5-year os rate of 50.2% ± 9.6% in this study is 
in keeping with previous reports 2,7,10,14–17, with most 
relapses occurring within the first year after diagnosis 
(median: 7 months).
Desmoplastic medulloblastoma histology was 
found in 24% of the patients, a frequency lower than 
that found in three recent multicentric trials, which 
demonstrated frequency ranges between 33% and 
46% in patients with infant medulloblastoma 8,9,18. 
This variation in frequency highlights the importance 
of uniformity in diagnostic criteria for desmoplasia 19, 
because desmoplastic histology appears to be associ-
ated with better outcome and has been proposed as a 
major element for risk stratification in future infant 
medulloblastoma protocols 20,21. The reason for the 
lack of prognostic correlation with desmoplastic his-
tology in our series is unclear, but is likely influenced 
by the heterogeneity in treatment received by our 
group of patients.
At diagnosis, 15 patients (52%) had metastatic 
disease. The actual frequency may be even higher in 
light of the 20% of patients whose records lacked a 
complete staging evaluation. The high incidence of 
disease dissemination is consistent with several other 
institutional and cooperative group reports 2,22,23. Al-
though nonsignificant, a trend to better outcomes in 
patients with metastatic disease was observed (p = 
0.055). This contra-intuitive trend can likely be ex-
plained by differences in treatment. The use of adjuvant 
radiotherapy was significantly associated with a better 
survival rate (p = 0.032), and of the metastatic patients, 
66% received radiation as compared with 14% of the 
M0 patients. Similar trends were reported by Walter et 
al. 2 in a population with infant medulloblastoma treated 
with chemotherapy and deferred radiotherapy.
We also did not find a significant correlation be-
tween extent of surgical resection and survival, most 
likely because of the small sample size in this series. 
However, in most recent infant studies, the associa-
tion of extent of resection with metastatic status at 
diagnosis has allowed for the identification of risk 
groups—such as older children—with significant 
differences in outcome8,9,18,24.
In our study, half the patients who received high-
dose chemotherapy with scr are long-term survivors. 
Longer follow-up is necessary, because this finding 
relates to the more recent cohort. However, these 
results appear encouraging and should be confirmed 
in larger prospective clinical trials that include a 
systematic neurocognitive evaluation of long-term 
survivors18,25,26.
Although there is growing evidence that omission 
or delay of radiation in infants allows for preservation 
of intellectual outcome, neurocognitive evaluations 
remain critical to appraising the benefits of the new 
strategies 4,8,9,27. Among the available evaluations, 
the best approach remains to be determined, not only 
for assessing the neurocognitive effects of first-line 
therapy, but also for evaluating the consequences of 
additional salvage therapy in patients whose initial 
treatment fails. For instance, in a group of patients 
treated with salvage therapy (including high-dose 
chemotherapy and focal radiation), Grill et al. 8 
reported a mean iq of 72 as compared with 91 in 
the group of survivors who received conventional 
chemotherapy only. Similarly, the German  ghop 
group (Gesellschaft fur Padiatrische Onkologie und 
Hamatologie) reported neurocognitive data on in- ) reported neurocognitive data on in-
fants treated with methotrexate-based chemotherapy 
(high-dose systemic, and intraventricular). Although 
the intellectual outcomes in their series appear to be 
improved compared with a historical control group 
treated with radiation, the ghop data also suggested 
significant decline in intellectual performance for 
patients who received salvage radiation after metho-
trexate therapy 9.
With few exceptions, most infant series in the 
literature are limited in their evaluation of intellec-
tual functioning. Deficits in other neurocognitive 
domains have been documented in older children 
with brain tumours treated with cranial radiation. 
Few attempts have been made to examine broader 
areas of function in children during infancy or early 
childhood 12. Our study contributes to this field by 
assessing, in a longitudinal fashion, multiple areas of 
neurocognitive functioning in long-term survivors. 
We present further evidence that strategies avoiding 
csi in infants are associated with preserved neu-
rocognitive outcome. At a mean interval of 5 years 
after diagnosis, patients who received csi showed, as 
expected, evidence of poor neurocognitive outcome 
across most measures. In this subgroup, standard iq 
scores were at least 2 standard deviations below the 
associated normative means. Standard scores for 
patients treated with chemotherapy alone or with 
a reduced radiation field were significantly higher, 
falling within the average range.
A significant observation in our series was that 
patients treated with less-intensive therapy demon-
strated improvement in intellectual functioning over 
time. Serial assessments are important not only for 
monitoring functional declines in highly vulnerable 27
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patients (such as those treated with cranial radiation), 
but also for documenting improvement in patients 
treated with less-intensive therapy. This improve-
ment may reflect functional normalization as the 
medical condition of these children improved follow-
ing illness and as they experienced increased learning 
opportunities that stimulated their behavioural and 
cognitive development.
Several studies have reported continuous neu-
rocognitive decline after cranial radiation 2,27–30. In 
our cohort of survivors, although patients treated with 
conventional csi demonstrated no functional declines 
across the two assessments, their scores were already 
at the lowest level by the time of the first assessment, 
which was performed 3.93 years after diagnosis. 
Hence, room for further decline was limited. Despite 
the pervasive neurocognitive deficits in patients 
treated with adjuvant csi at a young age, some areas 
of neurocognitive function were preserved. Notably, 
these patients demonstrated low-average function on a 
measure of receptive vocabulary. Indices of receptive 
vocabulary have been found to be relatively robust 
to the effects of cranial radiation in older children 31. 
Thus, by examining multiple domains of neurocog-
nitive function, we were able to identify an isolated 
area of relative strength in patients who typically 
present with other pervasive deficits. It is therefore 
important to ensure that all patients have access to 
comprehensive neuropsychological assessment, 
because identification of areas of relative strength is 
important for programming and developing compen-
satory strategies.
6.  CONCLUSIONS
This institutional review provides comprehensive 
longitudinal outcome and neurocognitive data on a 
population of infants successfully treated for medullo-
blastoma. Our study provides further indications that 
alternative therapeutic approaches, such as adjuvant 
chemotherapy and reduced or no radiation, are as-
sociated with encouraging intellectual performances. 
Efforts are required to better integrate neuropsycho-
logical evaluation into the objectives of future infant 
medulloblastoma protocols.
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